Domainex and Pharmidex Announce Drug Discovery Services Alliance
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Domainex Ltd and Pharmidex announced the formation of a strategic alliance, combining their expertise and technologies to provide the market with an integrated, high-quality drug discovery services platform.
The joint service offering will amalgamate Domainex’s LeadBuilder technology for hit-finding, as well as its highly-experienced medicinal chemistry team, with Pharmidex’s renowned expertise and in vitro and in vivo capabilities in drug metabolism and pharmacokinetics (DMPK).
Concordant with the established track records of both partners, the alliance will have a particular emphasis on tackling the most challenging of scientific problems, including novel or “difficult” drug targets.
The joint service offering will amalgamate Domainex’s LeadBuilder technology for hit-finding, as well as its highly-experienced medicinal chemistry team, with Pharmidex’s renowned expertise and in vitro and in vivo capabilities in drug metabolism and pharmacokinetics (DMPK).
Concordant with the established track records of both partners, the alliance will have a particular emphasis on tackling the most challenging of scientific problems, including novel or “difficult” drug targets.
